Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 431, Issue 4, Pages 647-651Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2013.01.041
Keywords
Nitric oxide; Cancer therapy; Adjuvant therapy; Pro-drugs; Cell signaling
Categories
Funding
- National Science Foundation [1060548]
- CVMBS College Council
- Flint Animal Cancer Center
- Department of Defense Congressionally Directed Research Program [DOD-CDMRP W81XWH-11-2-0113]
- Direct For Education and Human Resources
- Division Of Undergraduate Education [1060548] Funding Source: National Science Foundation
Ask authors/readers for more resources
Tumor resistance to cytotoxic therapeutics coupled with dose-limiting toxicity is a serious hurdle in the field of medical oncology. In the face of this obstacle, nitric oxide has emerged as a powerful adjuvant for the hypersensitization of tumors to more traditional chemo- and radio-therapeutics. Furthermore, emerging evidence indicates that nitric oxide donors have the potential to function independently in the clinical management of cancer. Herein, we discuss the role of nitric oxide in cancer and the potential for nitric oxide donors to support conventional therapeutics. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
